Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Director/PDMR Shareholding

23 Apr 2019 10:58

RNS Number : 8017W
Premier Veterinary Group PLC
23 April 2019
 

 

 

PREMIER VETERINARY GROUP PLC

 

NOTIFICATION OF TRANSACTIONS OF PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES (PDMR)

 

London, UK, 23rd April 2019 (LSE: PVG): Premier Veterinary Group plc (the "Company") has received notification that on 18th April 2019 Rajan Uppal, a Director of the Company, sold 265,000 ordinary shares of 10 pence each in the Company held in the name of Diagonal Nominees Limited to his wife's Self-Invested Personal Pension. The sale was made at 44.5 pence per ordinary share.

 

Following this transaction, there has been no change to the total beneficial holding of Mr Uppal, and he continues to be interested in 5,421,138 ordinary shares (which represents approximately 35.32% of the Company's issued share capital) as follows:

 

RAJAN UPPAL:

Diagonal Nominees Limited

4,173,751

Rensburg Nominees Limited (SIPP)

846,500

Thomas Grant & Company Nominees Limited

63,387

Lynchwood Nominees Limited (ISA)

60,000

TRACEY UPPAL:

Lynchwood Nominees Limited (ISA)

12,500

Alliance Trust Savings Nominees Limited (SIPP)

265,000

The total number of ordinary shares of 10 pence each in the capital of the Company in issue as at the date of this notice is 15,346,950 with each share carrying the right to one vote. There are no shares held in treasury. The total number of voting rights, therefore, in the Company is 15,346,950.

 

The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company.

 

The relevant notifications set out below are provided in accordance with the requirements of Article 19 of the EU Market Abuse Regulation.

 

1

Details of the person discharging managerial responsibilities/person closely associated 

 

a)

Name 

 

Rajan Uppal

 

2

Reason for the notification

 

a)

Position/status

 

Director

b)

Initial notification/ Amendment

 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name

 

Premier Veterinary Group plc

b)

LEI

 

 2138009B5L8VQUZ9A719

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 

 

a)

Description of the financial instrument, type of instrument

Identification code 

 

Ordinary Shares of £0.10 each

 

 

ISIN: GB00BSZLMS59

b)

Nature of the transaction

Sale of 265,000 ordinary shares from personal holding to wife's SIPP. There was no change in total beneficial holding.

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s) 

0.445

265,000 shares

 

d)

Aggregated information

 

- Aggregated volume

- Price 

 

 

 

Aggregate Price

Aggregate Volume

Aggregate Total

 

N/A

N/A

N/A

e)

Date of the transaction

 

18th April 2019 

f)

Place of the transaction

 

London

 

For further information, please contact:

 

Premier Veterinary Group plc

Dominic Tonner, Chief Executive Officer

Andrew Paull, Chief Financial Officer

Tel:  +44(0)117 970 4127

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHLIFEASSIVFIA
Date   Source Headline
1st Mar 201310:50 amRNSForm 8.3 - [Ark Therapeutics]
26th Feb 20135:35 pmRNSHolding(s) in Company
26th Feb 20139:33 amRNSForm 8.3 - Ark Therapeutics Group PLC
25th Feb 201311:55 amRNSForm 8.3 - Ark Therapeutics Group PLC
25th Feb 201311:27 amRNSHolding(s) in Company
22nd Feb 20132:41 pmRNSHolding(s) in Company
21st Feb 20131:24 pmPRNForm 8.3 - Ark Therapeutics plc
21st Feb 201310:56 amRNSHolding(s) in Company
20th Feb 201312:54 pmPRNForm 8.3 - Ark Therapeutics plc
20th Feb 201312:11 pmRNSForm 8.3 - [Ark Therapeutics Group PLC]
19th Feb 20134:40 pmRNSSecond Price Monitoring Extn
19th Feb 20134:35 pmRNSPrice Monitoring Extension
15th Feb 201312:57 pmRNSForm 8.3 - Ark Therapeutics Group PLC
15th Feb 201310:39 amPRNForm 8.3 - Ark Therapeutics Group plc
12th Feb 201312:25 pmRNSHolding(s) in Company
7th Feb 20133:05 pmRNSHolding(s) in Company
7th Feb 20131:41 pmPRNForm 8.3 - Ark Therapeutics Group
6th Feb 20134:43 pmRNSForm 8.3 - Ark Therapeutics
6th Feb 201311:18 amPRNForm 8.3 - Ark Therapeutics Group
6th Feb 201311:02 amRNSForm 8 (OPD)
5th Feb 20134:35 pmRNSPrice Monitoring Extension
5th Feb 20132:48 pmRNSForm 8.3 - Ark Therapeutics Group PLC
4th Feb 20132:43 pmRNSForm 8.3 - Ark Therapeutics Group Plc
4th Feb 20131:10 pmRNSForm 8.3 - Ark Therapeutics
4th Feb 201310:11 amRNSForm 8.3 - [Ark Therapeutics]
1st Feb 20133:10 pmRNSForm 8.3 - Ark Therapeutics Group PLC
1st Feb 20132:53 pmRNSForm 8.3 - Ark Therapeutics Amendment
1st Feb 201312:41 pmRNSForm 8.3 - Ark Therapeutics Group plc
31st Jan 20133:42 pmRNSForm 8.3 - Ark Therapeutics Group PLC
31st Jan 20131:40 pmRNSForm 8.3 - Ark Therapeutics Group Plc
31st Jan 20131:31 pmRNSForm 8.3 - Ark Therapeutics Group plc
31st Jan 201312:02 pmRNSForm 8.3 - ARK Therapeutics plc
31st Jan 201311:51 amBUSForm 8.3 - Ark Therapeutics Group Plc
31st Jan 201311:14 amPRNForm 8.3 - Ark Therapeutics Group
30th Jan 20134:03 pmRNSForm 8.3 - Ark Therapeutics Group Plc
30th Jan 20137:00 amRNSStrategic Review Update
24th Jan 20133:33 pmRNSHolding(s) in Company
21st Jan 20137:00 amRNSCompany Update
4th Dec 20123:40 pmRNSBlocklisting Six Monthly Return
30th Nov 20127:00 amRNSFrench Tax Credit for Research and Development
8th Nov 20127:00 amRNSInterim Management Statement
15th Oct 20127:00 amRNSRe Agreement
26th Sep 20127:00 amRNSManufacturing Agreement Update
29th Aug 20127:00 amRNSHalf Yearly Report
24th Aug 20124:40 pmRNSSecond Price Monitoring Extn
24th Aug 20124:35 pmRNSPrice Monitoring Extension
14th Aug 20127:00 amRNSRe Agreement
25th Jul 20127:00 amRNSManufacturing Partnership
5th Jul 20127:00 amRNSDirectorate Change
11th Jun 20127:00 amRNSAppointment of New Head of Business Development

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.